Navigation Links
Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
Date:2/11/2008

uccessfully develop compounds and its receipt of milestones and royalties from the collaborations, Pharmacopeia's anticipated operating results, financial condition, liquidity and capital resources, Pharmacopeia's expectations concerning the legal protections afforded by U.S. and international patent law, Pharmacopeia's ability to pursue the development of new compounds and other business matters without infringing the patent rights of others, additional competition, and changes in economic conditions.

Further information about these and other relevant risks and uncertainties may be found in Pharmacopeia's Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Pharmacopeia urges you to carefully review and consider the disclosures found in its filings which are available in the SEC EDGAR database at http://www.sec.gov and from Pharmacopeia at http://www.pharmacopeia.com. All forward-looking statements in this press release and oral statements made with respect to information contained in this press release are qualified entirely by the cautionary statements included in this press release and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by such forward-looking statements. These forward-looking statements speak only as of the date of this press release. Pharmacopeia undertakes no obligation to (and expressly disclaims any such obligation to) publicly update or revise the statements made herein or the risk factors that may relate thereto whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacopeia to Present at BIO CEO & Investor Conference 2008
2. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
3. Pharmacopeia Announces Third Quarter 2007 Financial Results
4. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
5. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
6. Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)
7. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
10. Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via Hydration of Red Blood Cells
11. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Mass. , Dec. 18, 2014  Decision Resources ... the United States will increase to ... will be primarily driven by expansion in the large ... energy devices will be increasingly adopted due to the ... Other key findings from Decision Resources Group,s ...
(Date:12/19/2014)... 18, 2014   Aratana Therapeutics, Inc . ... focused on the licensing, development and commercialization of ... results from its pivotal field study of AT-001 ... in dogs with osteoarthritis.  In the study, dogs ... that were statistically significant compared to placebo (p<0.05) ...
(Date:12/17/2014)... Revenue and earnings above the previous ... development In the past 2013/14 fiscal year (ended ... to EUR 4.287 billion (last year: EUR 4.190 billion) despite ... EUR 360 million. "Overall, 2013/14 was a successful fiscal year ... President and CEO of Carl Zeiss AG. "Thanks to our ...
Breaking Medicine Technology:U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS Asserts its Position in Difficult Environment 2
... 18 Epiphany Biosciences announced results from its Phase ... shingles (herpes zoster) infection. The study,s primary endpoint ... in terms of time to complete crusting of the ... randomized into 3 arms: 1 gram of once-daily ...
... Nov. 18 Covance Inc. (NYSE: CVD ), ... it entered into a biomarker alliance and services agreement with ... biomarker testing to the pharmaceutical industry. , Subject to the ... exclusive third-party provider of multiplexed protein biomarker testing services, and ...
Cached Medicine Technology:Epiphany Announces Positive Results from Its Phase 2b Trial in Shingles. 2Epiphany Announces Positive Results from Its Phase 2b Trial in Shingles. 3Covance Enters Into a Biomarker Alliance With Rules-Based Medicine, Inc. 2Covance Enters Into a Biomarker Alliance With Rules-Based Medicine, Inc. 3Covance Enters Into a Biomarker Alliance With Rules-Based Medicine, Inc. 4
(Date:12/17/2014)... Nwe is the co-author of a new weight loss book ... the Ace Medical Weight Loss Center in Rock Hill, SC. ... the industry of weight loss, and how several fad diets ... television shows, however, she says the topic of obesity is ... basic laughs, which she believes impacts whether Americans view it ...
(Date:12/17/2014)... RI (PRWEB) December 17, 2014 ... recognize private practices that have made outstanding and ... in support and progression of private practice physical ... American Physical Therapy Association. , On behalf of ... OCS, owner and CEO of Performance accepted the ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 A group of ... for Longevity, today, in reaction to a recent statement by ... of brain training and derogated the efficacy of all brain ... agreed with the parts of the center’s statement critical of ... the center had also overstated its case, in a document ...
(Date:12/17/2014)... No matter how far modern medicine advances, ... head louse parasite—a common childhood malady and a source ... six and twelve million individuals will suffer an infestation. ... company comes to the rescue, providing an all-natural treatment ... track record of customer service, and effectiveness in getting ...
(Date:12/17/2014)... 2014 Project Veritas is releasing a ... of MIT economist and Obamacare architect Jonathan Gruber to ... conducted the interview, which is being distributed on YouTube. ... intentional mislabeling in the Affordable Care Act in order ... two-hundred-and-fifty billion dollar per year tax grab. , “President ...
Breaking Medicine News(10 mins):Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2
... Attacks New York Department of ,Hype, with New York Times Ad ... (CCF) is running a full-page ad in the New York Times ... Department of Health,s hyperbolic "Don,t drink yourself fat" PSA campaign. The Center ... News and New York Post that ask New Yorkers, ...
... economic times, many business owners cut back and take a ... area cosmetic surgeon, has watched other cosmetic practices lock their ... conclusion that his medical spa and surgery center simply will ... to open another location in the ,Uptown, Dallas area. "I ...
... Oct. 1 Today, MSN released ... that helps people manage their health information on the Web. ... a variety of tools and widgets to upload, organize and ... The new service allows people to research medical concerns, read ...
... ... in stock, but supplies are expected to sell out quickly. Businesses and schools ... Purell on hand before the demand peaks as a result of the H1N1 ... company has 4.25 oz bottles, 12 oz pump bottles, 8 oz pump bottles ...
... ... the eleventh edition of the Biotech Beach™ Hotbed Campaign this morning. , ... Englewood, CO (Vocus) October 1, ... unveiled the eleventh edition of the Biotech Beach™ Hotbed Campaign this morning. , , ...
... ... TCSterps On-Demand, a comprehensive Video Relay Interpreting (VRI) service providing Sign Language Interpreting ... ... -- TCS Associates , ( http://www.TCSassociates.com ) a total solutions provider for ...
Cached Medicine News:Health News:Consumer Group Continues Million Dollar Campaign Responding to NYC Health Officials' Hyperbolic PSA Campaign 2Health News:Beauty and the Economy: Unusual Timing for Dallas Uptown Medi-Spa Launch 2Health News:Beauty and the Economy: Unusual Timing for Dallas Uptown Medi-Spa Launch 3Health News:MSN Introduces Online Tools to Help People Make Smarter Health and Lifestyle Decisions 2Health News:MSN Introduces Online Tools to Help People Make Smarter Health and Lifestyle Decisions 3Health News:Swine Flu Expected to Hit Hard - Purell Hand Sanitizer in Stock at CleanItSupply.com 2Health News:Swine Flu Expected to Hit Hard - Purell Hand Sanitizer in Stock at CleanItSupply.com 3Health News:BioSpace Launches the 2010 Biotech Beach Hotbed Campaign 2Health News:TCS Associates: A Sign Language Interpreting Agency Launches New Video Remote Interpreting (VRI) Service called TCSterps On-Demand 2Health News:TCS Associates: A Sign Language Interpreting Agency Launches New Video Remote Interpreting (VRI) Service called TCSterps On-Demand 3
... Engine instrument is the cycler that ... thermal uniformity and swappable blocks ensure ... This rugged machine is more ... platform for new features and upgrades ...
MBS 0.5 ml satellite block unit with height adjusting heated lid, 96 standard well block - holds up to 48 x 0.5ml tubes or 96 x 0.3ml tubes, includes tube thermistor)...
... Block MBS Start up kit. Includes configured ... of 1 MultiBlock satellite thermal Cycler ... User friendly software. Store/track run ... heated lid. Outstanding uniformity. Advanced ...
... The PxE Thermal Cycler (PxE) is a ... all fundamental features for value for money thermal ... of Thermo's sixteen years experience in manufacturing and ... that is synonymous with other products in the ...
Medicine Products: